AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03769675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Spinal Cord Stimulator
Description: The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .
Study NCT02613429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: identification of the airway by from the cranial end
Description: The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally
Study NCT02613429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: identification of the airway from the distal end
Description: The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
Study NCT00550771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab
Description: doxorubicin 60 mg/m\^2 IV push + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
Study NCT00550771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD, cyclophosphamide, trastuzumab, paclitaxel
Description: PLD 35 mg/m\^2 IV over 60 minutes + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
Study NCT00535795 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation Therapy
Study NCT00535795 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy
Study NCT04201717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic assisted left colectomy
Description: All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
Study NCT04201717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total laparoscopic left colectomy
Description: All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, all surgical area was flushed and drainage tubes were left.
Study NCT02921152 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bone marrow aspiration /trephine biopsy
Study NCT02335398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
Study NCT01742949 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated humidification (ThermoSmart)
Description: Heated Humidification (ThermoSmart) Turned On
Study NCT01742949 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No Humidification
Description: Heated Humidification (ThermoSmart) Turn Off
Study NCT02505334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Injected subcutaneously s.c. (under the skin) once daily.
Study NCT02505334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected subcutaneously s.c. (under the skin) once daily.
Study NCT02303847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
Study NCT00476892 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pelvic Floor Muscle Training
Description: Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
Study NCT00888602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3.4 g psyllium
Description: 3.4 g psyllium served with meal
Study NCT00888602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.8 g psyllium
Description: 6.8 g psyllium served with a meal
Study NCT00888602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.8 g psyllium
Description: 6.8 g psyllium
Study NCT00888602 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Meal
Description: meal
Study NCT00091637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexelizumab
Description: Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
Study NCT00091637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: bolus infusion over a 10 minute period once
Study NCT00274443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007 (Abraxane) and Carboplatin
Description: ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
Study NCT06073275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice ingestion
Description: Beetroot juice ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
Study NCT06073275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ingestion
Description: Placebo ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
Study NCT03589963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postnatal Lactation Support
Description: In-home breastfeeding support delivered by professional lactation consultants and provision of a high-quality breast pump
Study NCT03594019 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Connective tissue graft
Description: Connective tissue graft (CTG) is an oral and maxillofacial surgical procedure first described by Alan Edel in 1974. It includes the preparation the recipient site of tissue exhibiting recession by incising the gingival, obtaining the CTG from the donor site, securing the CTG at the recipient site and suturing the incised gingival tissue at both the donor and recipient sites.
Study NCT03594019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket shield technique
Description: The procedure is used to split the teeth and preserve the buccal part
Study NCT03594019 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate implant placement
Description: The implant will be placed in the frest socket immediately after tooth extraction
Study NCT03594019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Description: The implant will be placed in the frest socket immediately after tooth extraction
Study NCT02342548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg BID of PF-02545920
Description: All subject who completed A8241021 will receive 20 mg BID (with or without titration)
Study NCT04486170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education provided via a video format
Description: The intervention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room and the investigator will step outside. At the conclusion of the video, the investigator will return into the patient room and provide a pamphlet with similar information that was discussed in the video for them to take home.
Study NCT02063048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Based Weight Loss Support
Study NCT01454843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided LASIK - Allegretto
Description: Wavefront-guided LASIK using the Allegretto excimer laser for myopia.
Study NCT01454843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided LASIK - AMO
Description: Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
Study NCT03067675 — intervention group
Intervention type: DEVICE
Intervention: Topcon DRI OCT Triton (plus)
Description: OCT Machine used for diagnostic purposes
Study NCT02672332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Once daily
Study NCT02672332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Placebo comparator
Study NCT00201240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ selection with CliniMACS device
Description: CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ >5 x 10\*6/kg and CD3+ \< 1 x 10\*5/kg
Study NCT01793688 — intervention group
Intervention type: DRUG
Intervention: Sulbactam Sodium/Ampicillin Sodium
Description: Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).
Study NCT03379844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolization
Description: An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.
Study NCT00715104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T with Booster
Description: Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
Study NCT00715104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T without Booster
Description: Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
Study NCT02781181 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CAS with CPD
Description: using a neuroprotection device
Study NCT02781181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAS without CPD
Description: No Neuroprotection
Study NCT02132975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsies using Apollo and UroStation®
Description: Apollo : Motorised probe handler for prostate biopsies
Study NCT02132975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies using UroStation® (image fusion)
Study NCT00919997 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Description: Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
Study NCT00919997 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
Study NCT00919997 — intervention group
Intervention type: OTHER
Intervention: fluorescence activated cell sorting
Description: Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
Study NCT00919997 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
Study NCT02542800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic memory task
Study NCT00919997 — intervention group
Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables
Description: Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
Study NCT00919997 — intervention group
Intervention type: PROCEDURE
Intervention: study of high risk factors
Description: Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
Study NCT02222831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Day 0 denudation and time lapse culture on IVF-oocytes.
Study NCT04326868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzimidazole Anthelmintic
Description: The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
Study NCT04326868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzimidazole Anthelmintic
Description: The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
Study NCT01903785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: 60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
Study NCT01903785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01618851 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with IMRT and CyberKnife Boost
Description: Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.~The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.~For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions.
Study NCT02941796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1105
Study NCT02941796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0918
Study NCT02941796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0816
Study NCT01451138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured dermal and epidermal cells
Description: A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
Study NCT00800813 — intervention group
Intervention type: BEHAVIORAL
Intervention: Penile Exam, Peyronie's Plaque and Erectile function assessment
Description: At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level.
Study NCT02622841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BLEND
Description: Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
Study NCT02542800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Study NCT02178397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERLOTINIB WITH CHEMOTHERAPY
Study NCT02178397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHEMOTHERAPY ONLY
Study NCT01501747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine, paracetamol, cephalexin, or ibuprofen
Description: The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
Study NCT01501747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)
Description: The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
Study NCT04608032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder
Description: The first group will have \[Eco-Sz\] Ecological Cognitive training program for schizophrenia spectrum disorder
Study NCT04608032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recovery-Oriented Therapy
Description: The second group will have \[THoR\] Recovery-Oriented Therapy
Study NCT03357471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: e-Device
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical form: Solution for injection~* Route of administration: subcutaneous injection by e-Device
Study NCT04832581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Self-Care Behavior Development Program
Description: This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
Study NCT04420741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
Study NCT04420741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Continuously infusion for 72 hours at 3 ml/hours